tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2012 Jan 1;8(1). [Epub ahead of print]
New technologies for influenza vaccines.
Dormitzer P, Tsai T, Del Giudice G.
Source
Novartis Vaccines and Diagnostics; Cambridge, MA USA.
Abstract
Influenza vaccine preparations have been administered to humans since the late 1930s, ( 1) and the diversity of approaches in licensed trivalent seasonal or monovalent pandemic products is unparalleled by vaccines against any other target. These approaches include inactivated whole virus vaccines; detergent or solvent "split" vaccines; subunit vaccines; live attenuated vaccines; adjuvanted vaccines; intramuscular, intradermal, and intranasal vaccines; egg-produced vaccines; and mammalian cell culture-produced vaccines. The challenges of influenza immunization - multiple co-circulating strains, antigenic change over time, a broad age spectrum of disease, and the threat of pandemics - continue to drive the development of new approaches. This review describes some of the new approaches to influenza immunization that are the subjects of active research and development.
PMID:
22251994
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22251994
New technologies for influenza vaccines.
Dormitzer P, Tsai T, Del Giudice G.
Source
Novartis Vaccines and Diagnostics; Cambridge, MA USA.
Abstract
Influenza vaccine preparations have been administered to humans since the late 1930s, ( 1) and the diversity of approaches in licensed trivalent seasonal or monovalent pandemic products is unparalleled by vaccines against any other target. These approaches include inactivated whole virus vaccines; detergent or solvent "split" vaccines; subunit vaccines; live attenuated vaccines; adjuvanted vaccines; intramuscular, intradermal, and intranasal vaccines; egg-produced vaccines; and mammalian cell culture-produced vaccines. The challenges of influenza immunization - multiple co-circulating strains, antigenic change over time, a broad age spectrum of disease, and the threat of pandemics - continue to drive the development of new approaches. This review describes some of the new approaches to influenza immunization that are the subjects of active research and development.
PMID:
22251994
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22251994